微脉冲刺港交所，2024年营收超6.5亿

Core Viewpoint - Weimai, a Chinese internet healthcare company, has officially submitted its listing application to the Hong Kong Stock Exchange, with CMB International and Deutsche Bank serving as joint sponsors [1] Company Overview - Founded in 2015 and headquartered in Hangzhou, Weimai focuses on full-course management in healthcare, establishing multidisciplinary health management teams through partnerships with public hospitals to provide comprehensive and continuous medical services [3] - As of now, Weimai's services are available in over 280 cities, collaborating with more than 4,700 hospitals, and has served over 1 billion patients [3] Financial Performance - According to the prospectus, Weimai's revenue is projected to increase from 512 million yuan in 2022 to 653 million yuan in 2024, representing a growth rate of 27.5%. This growth is attributed to the stable increase in revenue from full-course management services and the expansion of its healthcare service ecosystem [3] - The gross margin is expected to rise from 17.2% in 2022 to 19.9% in 2024 [3] Technological Advancements - Weimai's core competitive advantage lies in its AI technology. In 2023, the company launched CareGPT, the first health management large language model in China, and developed CareAI, an intelligent health management system that analyzes patient communication and provides multi-format health advice [3] - The implementation of AI technology marks Weimai's transition from a traditional medical service platform to an "AI + healthcare" service provider, further solidifying its leading position in full-course management [3] Investment and Funding - Since its inception, Weimai has completed eight rounds of financing from over ten well-known investment institutions, including Baidu Ventures, Qianji Capital, and Matrix Partners [4] - In January of this year, Weimai completed a 200 million yuan D round of financing, with new investors including Xinyin Investment and Qiushi Capital, while existing shareholders continued to increase their stakes. This round of financing will primarily support Weimai's research and development in disease management solutions and AI [4]